Marissa Wilck, Shaun Barnabas, Kulkanya Chokephaibulkit, Avy Violari, Pope Kosalaraksa, Svitlana Yesypenko, Iryna Chukhalova, Ron Dagan, Peter Richmond, Elena Mikviman, Leslie Morgan, Kristen Feemster, Robert Lupinacci, Joseph Chiarappa, Shabir A Madhi, Kara Bickham, Luwy Musey
OBJECTIVES: To evaluate the safety and immunogenicity of V114 (15-valent pneumococcal conjugate vaccine [PCV] containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 22F, 23F, 33F), followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 8 weeks later, in children living with HIV. DESIGN: This phase 3 study (NCT03921424) randomized participants 6-17 years of age with HIV (CD4+ T-cell count ≥200 cells/μl, plasma HIV RNA < 50 000 copies/ml) to receive V114 or 13-valent PCV (PCV13) in a double-blind manner on Day 1, followed by PPSV23 at Week 8...
March 20, 2023: AIDS